Home > Newsletters > Clinical Trials Advisor > EMA Proposes Co-Primary Endpoints in Acute Heart Failure Drug Trials
Clinical Trials Advisor
Oct. 25, 2012 | Vol. 17 No. 21
EMA Proposes Co-Primary Endpoints in Acute Heart Failure Drug Trials
Developers of acute heart failure drugs should conduct double-blind, randomized Phase III trials with co-primary endpoints, rather than composite endpoints, according to a European Medicines Agency (EMA) draft guideline.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.